
CLAIMS

1. A compound of formula (Ia):



(Ia)

wherein,

R^A is phenyl, phenyl fused to a 5-7 membered heterocyclic ring, 5-10 membered heteroaryl, or 5-6 membered heteroaryl fused to a 5-7 membered heterocyclic ring; wherein R^A is optionally substituted on an available atom by one or more R^{1A}, wherein each R^{1A} is independently selected from the group consisting of halo, $C_{1–6}$ alkyl, $C_{2–6}$ alkenyl, $C_{2–6}$ alkynyl, $C_{1–6}$ hydroxyalkyl, $C_{1–6}$ methoxyalkyl, $C_{1–6}$ haloalkyl, hydroxy, $OC_{1–6}$ alkyl, $OC_{1–6}$ hydroxyalkyl, $OC_{1–6}$ methoxyalkyl, $OC_{1–6}$ haloalkyl, cyano, $NR^{2A}R^{3A}$, C_{1-6} alkyl-$NR^{2A}R^{3A}$, $NHCOCH_3$, CO_2H, CH_2CO_2H, $CONR^{2A}R^{3A}$, $CH_2CONR^{2A}R^{3A}$, C_{3-6} cycloalkyl, oxo, and a 4 membered heterocyclic ring, wherein the 4 membered heterocyclic ring is optionally substituted by hydroxy;

R^{2A} and R^{3A} are independently selected from the group consisting of H and $C_{1–6}$ alkyl, or R^{2A} and R^{3A} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

Y^1, Y^2 and Y^3 are independently selected from the group consisting of CR^{4A} and N, wherein at least two of Y^1, Y^2 and Y^3 are CR^{4A};

wherein R^{4A} is selected from the group consisting of H, C_{1-3} alkyl, $C_{2–3}$ alkenyl, $C_{2–3}$ alkynyl, OR^{8A}, halo, cyano, methanesulfonyl, CF_3 and $NR^{8A}R^{9A}$;

wherein R^{8A} and R^{9A} are independently selected from the group consisting of H and C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted on an available carbon atom by one or more groups selected from halo, hydroxy, methoxy, CO_2H and $NR^{10A}R^{11A}$,

wherein R^{10A} and R^{11A} are independently selected from the group consisting of H and $C_{1–6}$ alkyl, or R^{10A} and R^{11A} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

or

Y^2 is absent and one of Y^1 and Y^3 is S, O or NR^{5A}, and the remaining Y^1 or Y^3 is N or CR^{6A};

wherein R^{5A} is H or C_{1-3} alkyl; and

R^{6A} is selected from the group consisting of H, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, OR^{12A}, halo, cyano, methanesulfonyl, CF_3 and $NR^{12A}R^{13A}$;

wherein R^{12A} and R^{13A} are independently selected from the group consisting of H and C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted on an available carbon atom by one or more groups selected from halo, hydroxy, methoxy, CO_2H and $NR^{14A}R^{15A}$,

wherein R^{14A} and R^{15A} are independently selected from the group consisting of H and C_{1-6} alkyl, or R^{14A} and R^{15A} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

R^B is phenyl, phenyl fused to a 5-7 membered heterocyclic ring, 5-10 membered heteroaryl, 5-6 membered heteroaryl fused to a 5-7 membered heterocyclic ring, 5-7 membered heterocyclyl or C_{3-6} cycloalkyl; wherein R^B is optionally substituted on an available atom by one or more R^{1B}, wherein each R^{1B} is independently selected from the group consisting of halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} methoxyalkyl, C_{1-6} haloalkyl, hydroxy, OC_{1-6} alkyl, OC_{1-6} hydroxyalkyl, OC_{1-6} methoxyalkyl, OC_{1-6} haloalkyl, cyano, $NR^{2B}R^{3B}$, C_{1-6} alkyl-$NR^{2B}R^{3B}$, $NHCOCH_3$, CO_2H, CH_2CO_2H, $CONR^{2B}R^{3B}$, $CH_2CONR^{2B}R^{3B}$, C_{3-6} cycloalkyl, oxo, and a 4 membered heterocyclic ring, wherein the 4 membered heterocyclic ring is optionally substituted by hydroxy;

R^{2B} and R^{3B} are independently selected from the group consisting of H and C_{1-6} alkyl, or R^{2B} and R^{3B} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

R^C is H, fluoro, C_{1-3} alkyl, C_{1-2} hydroxyalkyl or C_{1-2} methoxyalkyl;


R^D is H or fluoro;

m is 0 or 1; and

X is $S(=O)_{1-2}$, $-CH_2S(=O)_{1-2}-$, $S(=O)(=NH)$, $-S(=O)_2NH-$, $-NHS(=O)_2-$, CH_2 or CH_2NH-;

or a pharmaceutically acceptable salt and/or solvate thereof.

2. A compound of formula (Ia) according to claim 1, which is a compound of formula (Ib):



(Ib)

wherein,

R^{A} is phenyl, phenyl fused to a 5-7 membered heterocyclic ring, 5-10 membered heteroaryl, or 5-6 membered heteroaryl fused to a 5-7 membered heterocyclic ring; wherein R^{A} is optionally substituted on an available carbon or nitrogen atom by one or more R^{1A}, wherein each R^{1A} is independently selected from the group consisting of halo, $C_{1–6}$ alkyl, $C_{2–6}$ alkenyl, $C_{2–6}$ alkynyl, $C_{1–6}$ hydroxyalkyl, $C_{1–6}$ methoxyalkyl, $C_{1–6}$ haloalkyl, hydroxy, $OC_{1–6}$ alkyl, $OC_{1–6}$ hydroxyalkyl, $OC_{1–6}$ methoxyalkyl, $OC_{1–6}$ haloalkyl, cyano, $NR^{2A}R^{3A}$, C_{1-6} alkyl-$NR^{2A}R^{3A}$, $NHCOCH_3$, CO_2H, CH_2CO_2H, $CONR^{2A}R^{3A}$, $CH_2CONR^{2A}R^{3A}$, C_{3-6} cycloalkyl and oxo;

R^{2A} and R^{3A} are independently selected from the group consisting of H and $C_{1–6}$ alkyl, or R^{2A} and R^{3A} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

Y^{1}, Y^{2} and Y^{3} are independently selected from the group consisting of CR^{4A} and N, wherein at least two of Y^{1}, Y^{2} and Y^{3} are CR^{4A};

wherein R^{4A} is selected from the group consisting of H, C_{1-3} alkyl, $C_{2–3}$ alkenyl, $C_{2–3}$ alkynyl, OR^{8A}, halo, cyano, methanesulfonyl, CF_3 and $NR^{8A}R^{9A}$;

wherein R^{8A} and R^{9A} are independently selected from the group consisting of H and C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted on an available carbon atom by one or more groups selected from halo, hydroxy, methoxy, CO_2H and $NR^{10A}R^{11A}$,

wherein R^{10A} and R^{11A} are independently selected from the group consisting of H and $C_{1–6}$ alkyl, or R^{10A} and R^{11A} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

or

Y^{2} is absent and one of Y^{1} and Y^{3} is S, O or NR^{5A}, and the remaining Y^{1} or Y^{3} is N or CR^{6A};

wherein R^{5A} is H or C_{1-3} alkyl; and

R^{6A} is selected from the group consisting of H, C_{1-3} alkyl, $C_{2–3}$ alkenyl, $C_{2–3}$ alkynyl, OR^{12A}, halo, cyano, methanesulfonyl, CF_3 and $NR^{12A}R^{13A}$;

wherein R^{12A} and R^{13A} are independently selected from the group consisting of H and C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted on an available carbon atom by one or more groups selected from halo, hydroxy, methoxy, CO_2H and $NR^{14A}R^{15A}$,

wherein R^{14A} and R^{15A} are independently selected from the group consisting of H and $C_{1–6}$ alkyl, or R^{14A} and R^{15A} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

R^B is phenyl, phenyl fused to a 5-7 membered heterocyclic ring, 5-10 membered heteroaryl, 5-6 membered heteroaryl fused to a 5-7 membered heterocyclic ring, 5-7 membered heterocyclyl or C_{3-6} cycloalkyl; wherein R^B is optionally substituted on an available carbon or nitrogen atom by one or more R^{1B}, wherein each R^{1B} is independently selected from the group consisting of halo, $C_{1–6}$ alkyl, $C_{2–6}$ alkenyl, $C_{2–6}$ alkynyl, $C_{1–6}$ hydroxyalkyl, $C_{1–6}$ methoxyalkyl, $C_{1–6}$ haloalkyl, hydroxy, $OC_{1–6}$ alkyl, $OC_{1–6}$ hydroxyalkyl, $OC_{1–6}$ methoxyalkyl, $OC_{1–6}$ haloalkyl, cyano, $NR^{2B}R^{3B}$, C_{1-6} alkyl-$NR^{2B}R^{3B}$, $NHCOCH_3$, CO_2H, CH_2CO_2H, $CONR^{2B}R^{3B}$, $CH_2CONR^{2B}R^{3B}$, C_{3-6} cycloalkyl and oxo;

R^{2B} and R^{3B} are independently selected from the group consisting of H and $C_{1–6}$ alkyl, or R^{2B} and R^{3B} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

R^C is H, fluoro, $C_{1–3}$ alkyl, $C_{1–2}$ hydroxyalkyl or $C_{1–2}$ methoxyalkyl;


R^D is H or fluoro;

m is 0 or 1; and

X is $S(=O)_{1-2}$ or S(=O)(=NH);

or a pharmaceutically acceptable salt and/or solvate thereof.

3. A compound of formula (Ia) according to claim 1 or claim 2, which is a compound of formula (I):



(I)

wherein,

R^A is phenyl, phenyl fused to a 5-7 membered heterocyclic ring, 5-10 membered heteroaryl, or 5-6 membered heteroaryl fused to a 5-7 membered heterocyclic ring; wherein R^A is optionally substituted on an available carbon atom by one or more R^{1A}, wherein R^{1A} is independently selected from the group consisting of halo, $C_{1–6}$ alkyl, $C_{2–6}$ alkenyl, $C_{2–6}$ alkynyl, $C_{1–6}$ hydroxyalkyl, $C_{1–6}$ methoxyalkyl, $C_{1–6}$ haloalkyl, hydroxy, $OC_{1–6}$ alkyl, $OC_{1–6}$ hydroxyalkyl, $OC_{1–6}$ methoxyalkyl, $OC_{1–6}$ haloalkyl, cyano, $NR^{2A}R^{3A}$, C_{1-6} alkyl-$NR^{2A}R^{3A}$, $NHCOCH_3$, CO_2H, CH_2CO_2H, $CONR^{2A}R^{3A}$, $CH_2CONR^{2A}R^{3A}$, C_{3-6} cycloalkyl and oxo;

R^{2A} and R^{3A} are independently selected from the group consisting of H and $C_{1–6}$ alkyl, or R^{2A} and R^{3A} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

Y^1, Y^2 and Y^3 are independently selected from the group consisting of CR^{4A} and N, wherein at least two of Y^1, Y^2 and Y^3 are CR^{4A};

wherein R^{4A} is selected from the group consisting of H, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, OR^{8A}, halo, cyano, methanesulfonyl, CF_3 and $NR^{8A}R^{9A}$;

wherein R^{8A} and R^{9A} are independently selected from the group consisting of H and C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted on an available carbon atom by one or more groups selected from halo, hydroxy, methoxy, CO_2H and $NR^{10A}R^{11A}$,

wherein R^{10A} and R^{11A} are independently selected from the group consisting of H and C_{1-6} alkyl, or R^{10A} and R^{11A} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

or

Y^2 is absent and one of Y^1 and Y^3 is S, O or NR^{5A}, and the remaining Y^1 or Y^3 is N or CR^{6A};

wherein R^{5A} is H or C_{1-3} alkyl; and

R^{6A} is selected from the group consisting of H, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, OR^{12A}, halo, cyano, methanesulfonyl, CF_3 and $NR^{12A}R^{13A}$;

wherein R^{12A} and R^{13A} are independently selected from the group consisting of H and C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted on an available carbon atom by one or more groups selected from halo, hydroxy, methoxy, CO_2H and $NR^{14A}R^{15A}$,

wherein R^{14A} and R^{15A} are independently selected from the group consisting of H and C_{1-6} alkyl, or R^{14A} and R^{15A} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

R^B is phenyl, phenyl fused to a 5-7 membered heterocyclic ring, 5-10 membered heteroaryl, 5-6 membered heteroaryl fused to a 5-7 membered heterocyclic ring, 5-7 membered heterocyclyl or C_{3-6} cycloalkyl; wherein R^B is optionally substituted on an available carbon atom by one or more R^{1B}, wherein R^{1B} is independently selected from the group consisting of halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} methoxyalkyl, C_{1-6} haloalkyl, hydroxy, OC_{1-6} alkyl, OC_{1-6} hydroxyalkyl, OC_{1-6} methoxyalkyl, OC_{1-6} haloalkyl, cyano, $NR^{2B}R^{3B}$, C_{1-6} alkyl-$NR^{2B}R^{3B}$, $NHCOCH_3$, CO_2H, CH_2CO_2H, $CONR^{2B}R^{3B}$, $CH_2CONR^{2B}R^{3B}$, C_{3-6} cycloalkyl and oxo;

R^{2B} and R^{3B} are independently selected from the group consisting of H and C_{1-6} alkyl, or R^{2B} and R^{3B} together with the N atom to which they are attached combine to form a 4-7 membered heterocyclic ring which is optionally substituted on an available atom by one or more groups selected from C_{1-2} alkyl and oxo;

R^C is H, fluoro, $C_{1–3}$ alkyl, $C_{1–2}$ hydroxyalkyl or $C_{1–2}$ methoxyalkyl;

R^D is H or fluoro;

m is 0 or 1; and

X is $S(=O)_{1-2}$ or S(=O)(=NH);

or a pharmaceutically acceptable salt and/or solvate thereof.

4. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 3, wherein R^A phenyl, phenyl fused to a 5-6 membered heterocyclic ring (such as selected from the group consisting of 2,3-dihydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, benzo-1,4-dioxanyl, 1,3-benzodiazole and 3,4-dihydro-2H-1,4-benzoxazine), 5-6 membered heteroaryl (such as pyrrolyl, pyrazolyl, pyrimidinyl or pyridyl), or 5-6 membered heteroaryl fused to a 5-6 membered heterocyclic ring (such as 2,3-dihydropyrazolo[5,1-b]oxazolyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 2,3-dihydrofuro[3,2-b]pyridinyl, 2,3-dihydro-[1,4]dioxino[2,3-c]pyridinyl or 2,3-dihydro-[1,4]dioxino[2,3-b]pyridinyl), and is optionally substituted on an available atom (e.g. a carbon or nitrogen atom, in particular a carbon atom) by one or more R^{1A}.

5. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 4, wherein R^A is phenyl optionally substituted on an available carbon atom by one or more R^{1A}.

6. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 3, wherein R^A is 5-10 membered heteroaryl, such as selected from the group consisting of pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, oxazolyl, , isoxazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyradizinyl, pyrazinyl, furo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, indolyl, indazolyl, benzofuranyl, benzimidazolyl, benzothiazolyl, benzothiophenyl, quinolinyl, isoquinolinyl and quinazolinyl; and is optionally substituted on an available atom (e.g. a carbon or nitrogen atom, in particular a carbon atom) by one or more R^{1A}.

7. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 6, wherein each R^{1A} is independently selected from the group consisting of halo, $C_{1–6}$ alkyl, $C_{1–6}$ hydroxyalkyl, $C_{1–6}$ methoxyalkyl, $C_{1–6}$ haloalkyl, hydroxy, $OC_{1–6}$ alkyl, $OC_{1–6}$ hydroxyalkyl, $OC_{1–6}$ methoxyalkyl, $OC_{1–6}$ haloalkyl, cyano, $NR^{2A}R^{3A}$, $NHCOCH_3$, CO_2H, $CONR^{2A}R^{3A}$, C_{3-6} cycloalkyl, oxo, and a 4 membered heterocyclic ring, wherein the 4 membered heterocyclic ring is optionally substituted by hydroxy; and in particular is independently selected from halo, $C_{1–6}$ alkyl, $C_{1–6}$ hydroxyalkyl, $C_{1–6}$ methoxyalkyl, $C_{1–6}$ haloalkyl, hydroxy and $OC_{1–6}$ alkyl e.g. $C_{1–6}$ alkyl, $OC_{1–6}$ alkyl, oxo, and oxetane or azetidine either of which is optionally substituted

by hydroxy; e.g. is OCH_3.

8. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 6, wherein R^A is unsubstituted.

9. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 8, wherein R^B is phenyl optionally substituted on an available carbon atom by one or more R^{1B}.

10 The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 8, wherein R^B is 5-10 membered heteroaryl such as selected from the group consisting of pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, oxazolyl, isoxazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyradizinyl, pyrazinyl, furo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, indolyl, indazolyl, benzofuranyl, benzimidazolyl, benzothiazolyl, benzothiophenyl, quinolinyl, isoquinolinyl and quinazolinyl; and in particular is selected from the group consisting of furanyl, thienyl, pyrazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrazinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl and indazolyl e.g. is pyrazolyl; and is optionally substituted on an available atom (e.g. a carbon or nitrogen atom, in particular a carbon atom) by one or more R^{1B}.

11. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 8, wherein R^B is 5-6 membered heteroaryl fused to a 5-7 membered heterocyclic ring, such as 2,3-dihydropyrazolo[5,1-b]oxazolyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 2,3-dihydrofuro[3,2-b]pyridinyl, 2,3-dihydro-[1,4]dioxino[2,3-c]pyridinyl or 2,3-dihydro-[1,4]dioxino[2,3-b]pyridinyl; and is optionally substituted on an available atom (e.g. a carbon or nitrogen atom, in particular a carbon atom) by one or more R^{1B}.

12. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 11, wherein each R^{1B} is independently selected from the group consisting of halo, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} haloalkyl, hydroxy, OC_{1-6} alkyl, OC_{1-6} hydroxyalkyl, OC_{1-6} haloalkyl, cyano, $NR^{2B}R^{3B}$, $CONR^{2B}R^{3B}$, $CH_2CONR^{2B}R^{3B}$, C_{3-6} cycloalkyl, oxo, and a 4 membered heterocyclic ring, wherein the 4 membered heterocyclic ring is optionally substituted by hydroxy; and in particular is independently selected from the group consisting of fluoro, chloro, methyl, ethyl, CH_2OH, CH_2CH_2OH, CHF_2, hydroxy, OCH_3, OCH_2CH_2OH, $OCHF_2$, cyano, NH_2, $CONH_2$, $CONHCH_3$, CH_2CONH_2, cyclopropyl, oxo, and oxetane or azetidine either of which is optionally substituted by hydroxy.

13. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any

one of claims 1 to 11, wherein R^B is unsubstituted.

14. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 13, wherein Y^1, Y^2 and Y^3 are all CR^{4A}, wherein suitably R^{4A} is H.

15. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 14, wherein R^C is H and R^D is H.

16. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 15, wherein m is 0.

17. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 16, wherein X is $S(=O)_2$.

18. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1, selected from the group consisting of:
2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((4- methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-(indolin-4-ylmethyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-((2-hydroxypyridin-4-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
6-((4-methoxyphenyl)sulfonyl)-2-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)phthalazin-1(2H)-one;
2-((1-(2-hydroxyethyl)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-((5-hydroxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(2-methoxy-1-(6-methoxypyridin-3-yl)ethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinamide;
2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((1-ethyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((4-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)thiophene-2-carboxamide;
6-methoxy-3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinamide;
3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1H-pyrazole-4-carboxamide;
2-((1-(2-hydroxyethyl)-4-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
3-((6-((4-methoxyphenyl)sulfonyl)-1-oxophthalazin-2(1H)-yl)methyl)-N-methylfuran-2-carboxamide;
3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1H-pyrazole-4-carbonitrile;
2-(2-hydroxy-1-phenylethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;

2-(2-(hydroxymethyl)benzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((6-(2-hydroxyethoxy)pyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((2-(hydroxymethyl)thiophen-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)thiophene-2-carbonitrile;
2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-((5-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((4-(hydroxymethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((1-(difluoromethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((2-methylthiazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((5-methoxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(2-fluorobenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(2-fluoro-5-methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(imidazo[1,2-a]pyridin-5-ylmethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((1-methyl-1H-indazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((6-aminopyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((1-methyl-1H-indazol-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(3-(difluoromethoxy)benzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
6-((4-methoxyphenyl)sulfonyl)-2-(pyridin-3-ylmethyl)phthalazin-1(2H)-one;
2-(2-aminobenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
6-((4-methoxyphenyl)sulfonyl)-2-phenethylphthalazin-1(2H)-one;
2-(isoxazol-5-ylmethyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-(4-chloro-2-fluorobenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-((2,3-dihydrobenzofuran-5-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-indazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-(4-methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-benzyl-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
6-((4-methoxyphenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
2-(2-fluoro-3-methoxybenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-(2,6-difluoro-4-methoxybenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
6-((4-methoxyphenyl)sulfonyl)-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
2-((2-hydroxypyridin-4-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-((2-hydroxypyridin-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;

2-(benzo[d][1,3]dioxol-5-ylmethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((1H-indazol-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((5-methoxypyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(2-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)phenyl)acetamide;
2-((6-(difluoromethoxy)pyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(2-(2-hydroxyethyl)benzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((2-methyl-2,3-dihydrobenzofuran-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
6-(phenylsulfonyl)-2-(pyridin-3-ylmethyl)phthalazin-1(2H)-one;
2-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide;
2-(2-methoxy-1-phenylethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
6-(phenylsulfonyl)-2-(1-(pyridin-3-yl)ethyl)phthalazin-1(2H)-one;
2-((1,3-dimethyl-1H-pyrazol-4-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-benzyl-6-(phenylsulfonyl)phthalazin-1(2H)-one;
6-((4-methoxyphenyl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(1-(6-methoxypyridin-3-yl)ethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((6-methylpyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((4-chloro-1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((2-methylthiazol-4-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(difluoro(pyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(2-methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((5-methylisoxazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(3-methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(2-methoxy-1-phenylethyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-((1-ethyl-1H-pyrazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide;
3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)furan-2-carboxamide;
5-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)furan -2-carboxamide;
2-((5-methoxypyrazin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((2-methoxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((1,4-dimethyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-chloro-6-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide;
2-methoxy-6-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide;
4-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)thiazole-2-carboxamide;
5-methyl-4-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl) isoxazole-3-carboxamide;

2-((1-isopropyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((5-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((3-methylisothiazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((2-hydroxy-6-methylpyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
2-((2-hydroxy-4-methylpyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
2-((5-fluoro-2-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
2-((2-hydroxy-5-isopropylpyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
2-((4-chloro-2-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
2-((4-fluoro-2-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
6-((4-methoxyphenyl)sulfonyl)-2-((4-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
2-((3-hydroxypyridin-4-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
5-methoxy-2-((6-(4-methoxyphenylsulfonyl)-1-oxophthalazin-2(1H)-yl)methyl)benzamide;
2-((4-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
6-(phenylsulfonyl)-2-(pyrazolo[1,5-a]pyridin-2-ylmethyl)phthalazin-1(2H)-one;
2-((2-hydroxy-6-methoxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
2-((4-fluoro-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((5-fluoro-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
6-(4-methoxyphenylsulfonyl)-2-((3-(trifluoromethyl)isoxazol-5-yl)methyl)phthalazin-1(2H)-one;
6-(4-methoxyphenylsulfonyl)-2-((3-(trifluoromethyl)isoxazol-5-yl)methyl)phthalazin-1(2H)-one;
2-((3-hydroxypyridin-2-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
2-(3-aminobenzyl)-6-(quinolin-8-ylsulfonyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-(5-methylpyridin-2-ylsulfonyl)phthalazin-1(2H)-one;
6-(3-methoxyphenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
3-(2-((6-methoxypyridin-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylsulfonyl)thiophene-2-carboxamide;
4-(2-((6-methoxypyridin-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylsulfonyl)thiophene-2-carboxamide;
2-(3-aminobenzyl)-6-(phenylsulfinyl)phthalazine-1(2H)-one;
2-(3-aminobenzyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one;
2-(3-aminobenzyl)-6-(pyridin-3-ylsulfonyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-1-oxo-N-phenyl-1,2-dihydrophthalazine-6-sulfonamide;
6-((1H-indazol-4-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((6-(difluoromethoxy)pyridin-3-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
(R)-6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-

1(2H)-one;
(S)-6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one;
R)-2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one;
(S)-2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one;
6-(4-(difluoromethoxy)phenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
(R)-6-(4-(difluoromethoxy)phenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
(S)-6-(4-(difluoromethoxy)phenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
(R)-6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
(S)-6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-3-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
2-(3-aminobenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-(3-aminobenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one;
2-(3-aminobenzyl)-6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one;
2-(3-aminobenzyl)-6-(pyridin-2-ylsulfonyl)phthalazin-1(2H)-one;
2-(3-aminobenzyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one;
2-(3-aminobenzyl)-6-((5-methylthiophen-2-yl)sulfonyl)phthalazin-1(2H)-one;
6-((4-fluorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-(3-methylisothiazol-5-ylsulfonyl)phthalazin-1(2H)-one;
2-(3-aminobenzyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-tosylphthalazin-1(2H)-one;
2-(3-aminobenzyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazine-1(2H)-one;
2-(3-aminobenzyl)-6-(benzo[d][1,3]dioxol-5-ylsulfonyl)phthalazin-1(2H)-one;
6-(4-(difluoromethoxy)phenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((3-chlorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((4-chlorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((3-fluorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-(4-methylpyridin-2-ylsulfonyl)phthalazin-1(2H)-one;

6-(6-methoxypyridin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
3-(2-((6-methoxypyridin-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylsulfonyl)benzamide;
6-(2-fluorophenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(2-chlorophenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(2-methoxyphenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(4-methoxypyridin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-(6-methylpyridin-2-ylsulfonyl)phthalazin-1(2H)-one;
6-(3-(difluoromethoxy)phenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-(5-methylthiophen-2-ylsulfonyl)phthalazin-1(2H)-one;
6-(5-methoxypyridin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(2-(difluoromethyl)thiazol-5-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-(2-methylthiazol-4-ylsulfonyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-(6-methoxypyridin-3-ylsulfonyl)phthalazin-1(2H)-one;
2-((6-methoxypyridin-3-yl)methyl)-6-(2-methylbenzo[d]thiazol-4-ylsulfonyl)phthalazin-1(2H)-one;
6-(5-methoxypyrazin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(imidazo[1,2-a]pyridin-5-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(1-(difluoromethyl)-1H-pyrazol-3-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
(S)-6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((2,3-dihydrofuro[2,3-b]pyridin-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(imidazo[1,2-a]pyridin-7-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(1,2-dimethyl-1H-imidazol-4-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(1,5-dimethyl-1H-pyrazol-4-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
(S)-6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(1-cyclopropyl-1H-pyrazol-4-ylsulfonyl)-2-((2-hydroxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-(1-cyclopropyl-1H-pyrazol-4-ylsulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-(benzofuran-5-ylsulfonyl)phthalazin-1(2H)-one;

2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((1-cyclopropyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;

6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;

2-(3-(difluoromethoxy)benzyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one;

2-(2-fluoro-5-methoxybenzyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one;

2-((2-hydroxypyridin-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;

6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;

6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)sulfonyl)-2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;

2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one;

6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;

2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one;

6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;

2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)phthalazine-1(2H)-one;

6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((4-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;

6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;

2-((6-(1-methyl-1H-pyrazol-3-ylsulfonyl)-1-oxophthalazin-2(1H)-yl)methyl)benzamide;

2-((1H-pyrazol-3-yl)methyl)-6-(pyridin-2-ylsulfonyl)phthalazin-1(2H)-one;

6-((4-(difluoromethoxy)phenyl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;

2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one;

2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one;

6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;

6-((4-ethoxyphenyl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;

(R)-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one;

2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((4-(trifluoromethoxy)phenyl)sulfonyl)phthalazin-1(2H)-one;

(S)-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one;

2-((1H-pyrazol-3-yl)methyl)-6-((3-methylbenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-(benzofuran-6-ylsulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-(furo[3,2-b]pyridin-5-ylsulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((2-methylbenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-(furo[2,3-b]pyridin-5-ylsulfonyl)phthalazin-1(2H)-one;
6-((1H-indol-5-yl)sulfonyl)-2-((1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-(benzo[b]thiophen-5-ylsulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((1-cyclopropyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-indol-5-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-(pyridin-3-ylsulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-(1-(2-hydroxyethyl)-1H-pyrazol-3-ylsulfonyl)-2-((2-hydroxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-3-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
7-fluoro-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
5-fluoro-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
7-((2-hydroxyethyl)amino)-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
8-fluoro-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
7-((2-hydroxyethyl)amino)-2-((2-hydroxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
5-((2-hydroxyethyl)amino)-2-((2-hydroxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;

3-((1-methyl-1H-pyrazol-3-yl)methyl)-7-(phenylsulfonyl)pyrido[3,4-d]pyridazin-4(3H)-one;
3-((1-methyl-1H-pyrazol-3-yl)methyl)-7-(phenylsulfinyl)pyrido[3,4-d]pyridazin-4(3H)-one;
7-((1-methyl-1H-pyrazol-3-yl)methyl)-3-(phenylsulfonyl)pyrido[2,3-d]pyridazin-8(7H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((5-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((3-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
6-(1H-pyrazol-4-ylsulfonyl)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-(pyridin-4-ylsulfonyl)phthalazin-1(2H)-one;
2-((2,4-dihydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one;
2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-(furo[3,2-b]pyridin-5-ylsulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((5-methoxypyridin-2-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydrofuro[2,3-c]pyridin-5-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1-cyclopropyl-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-(pyrazin-2-ylsulfonyl)phthalazin-1(2H)-one;
2-(imidazo[1,2-a]pyridin-3-ylmethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-7-((2-hydroxyethyl)amino)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-7-((2-hydroxyethyl)amino)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
3-((1H-pyrazol-3-yl)methyl)-7-((1-methyl-1H-pyrazol-4-yl)sulfonyl)pyrido[3,4-d]pyridazin-4(3H)-one;
7-((1H-pyrazol-3-yl)methyl)-3-((1-methyl-1H-pyrazol-4-yl)sulfonyl)pyrido[2,3-d]pyridazin-8(7H)-one;
2-((1H-pyrazol-3-yl)methyl)-7-((2-hydroxyethyl)amino)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((6-methylpyridin-2-yl)methyl)-6-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1-(oxetan-3-yl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one;
2-((6-(1-hydroxyethyl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;

2-((6-cyclopropylpyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1-(azetidin-3-yl)-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
6-((1-(2-aminoethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
(S)-2-((6-(1-hydroxyethyl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
(R)-2-((6-(1-hydroxyethyl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
2-((6-(3-hydroxyoxetan-3-yl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1*H*-pyrazol-4-yl)sulfonyl)-2-((2-methoxypyridin-3-yl)methyl)phthalazin-1(2*H*)-one;
2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-2-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-cyclopropylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((6-methylpyridin-2-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((5-methylpyridin-2-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1*H*-pyrazol-3-yl)methyl)-6-((6-methylpyridin-3-yl)sulfonyl)phthalazin-1(2*H*)-one;
6-(1H-pyrazol-4-ylsulfonyl)-2-((5-methoxy-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
2-((1-(2-hydroxyethyl)-1*H*-pyrazol-3-yl)methyl)-6-((5-methoxypyridin-2-yl)sulfonyl)phthalazin-1(2*H*)-one;
6-(1H-pyrazol-4-ylsulfonyl)-2-((2,3-dihydrofuro[2,3-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-3-yl)methyl)phthalazin-1(2H)-one;
(R)-6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
(S)-6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-(furo[3,2-b]pyridin-5-ylmethyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-3-yl)sulfonyl)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one;
7-((1H-pyrazol-4-yl)sulfonyl)-3-((5-methyl-1H-pyrazol-3-yl)methyl)pyrido[3,4-d]pyridazin-4(3H)-one;

6-((1H-pyrazol-5-yl)sulfonyl)-2-((3-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-5-yl)sulfonyl)-2-((6-cyclopropylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-5-yl)sulfonyl)-2-((5-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one;
2-((6-cyclopropylpyridin-2-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((4-chloro-1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one;
2-((5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((4-methyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
6-((4-fluoro-1H-pyrazol-3-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
2-((5-chloro-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((3-chloro-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
6-((4-chloro-1H-pyrazol-3-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((3-fluoro-5,6-dimethylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
2-((5-fluoro-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)phthalazin-1(2H)-one;
2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-3-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((3-fluoro-6-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one;
2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-3-yl)sulfonyl)-2-((1-(difluoromethyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-3-yl)sulfonyl)-2-((3-fluoro-6-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one;

2-(furo[3,2-b]pyridin-5-ylmethyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
3-((5-methyl-1H-pyrazol-3-yl)methyl)-7-((1-methyl-1H-pyrazol-4-yl)sulfonyl)pyrido[3,4-d]pyridazin-4(3H)-one;
6-((1H-pyrazol-3-yl)sulfonyl)-2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-3-yl)sulfonyl)-2-(furo[3,2-b]pyridin-5-ylmethyl)phthalazin-1(2H)-one;
2-(furo[3,2-b]pyridin-5-ylmethyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one;
2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((4-chloro-1,5-dimethyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-5-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one ;
6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one;
2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-(1H-pyrazole-4-sulfonimidoyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((3,5-difluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one;
7-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)-3-((5-methyl-1H-pyrazol-3-yl)methyl)pyrido[3,4-d]pyridazin-4(3H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)methyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((2-methylfuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((2-cyclopropylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
7-((1H-pyrazol-4-yl)sulfonyl)-3-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)pyrido[3,4-d]pyridazin-4(3H)-one;
2-((4,5-dimethyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-(furo[3,2-b]pyridin-5-ylmethyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((3-fluoro-5,6-dimethylpyridin-2-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-

yl)sulfonyl)phthalazin-1(2H)-one;
6-((1H-pyrazol-4-yl)sulfonyl)-2-((3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl)phthalazin-1(2H)-one;
6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-2-((7-methyl-2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)phthalazin-1(2H)-one;
2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((5-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((5-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one;
2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-methoxyethyl)-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one;
2-((1H-pyrazol-3-yl)methyl)-6-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one;
2-[(7-methyl-2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl]-6-(1H-pyrazol-4-ylsulfonyl)phthalazin-1-one;
(R)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-(1H-pyrazole-4-sulfonimidoyl)phthalazin-1(2H)-one; and
(S)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-(1H-pyrazole-4-sulfonimidoyl)phthalazin-1(2H)-one;
or a pharmaceutically acceptable salt and/or solvate thereof.

19. A pharmaceutical composition comprising a compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 18, and one or more pharmaceutically acceptable diluents or carriers.

20. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 18 or a pharmaceutical composition according to claim 19, for use as a medicament.

21. Use of the compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 18, or a pharmaceutical composition according to claim 19, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition associated with the function of PK, in particular PKM2 and/or PKLR.

22. The use according to claim 21, wherein the medicament is for the treatment or prevention

of an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder.

23. The use according to claim 22, wherein the inflammatory disease or disease associated with an undesirable immune response is, or is associated with, a disease selected from the group consisting of: psoriasis (including chronic plaque, erythrodermic, pustular, guttate, inverse and nail variants), asthma, chronic obstructive pulmonary disease (COPD, including chronic bronchitis and emphysema), heart failure (including left ventricular failure), myocardial infarction, angina pectoris, other atherosclerosis and/or atherothrombosis-related disorders (including peripheral vascular disease and ischaemic stroke), a mitochondrial and neurodegenerative disease (such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, retinitis pigmentosa or mitochondrial encephalomyopathy), autoimmune paraneoplastic retinopathy, transplantation rejection (including antibody-mediated and T cell-mediated forms), multiple sclerosis, transverse myelitis, ischaemia-reperfusion injury (e.g. during elective surgery such as cardiopulmonary bypass for coronary artery bypass grafting or other cardiac surgery, following percutaneous coronary intervention, following treatment of acute ST-elevation myocardial infarction or ischaemic stroke, organ transplantation, or acute compartment syndrome), AGE-induced genome damage, an inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), primary sclerosing cholangitis (PSC), PSC-autoimmune hepatitis overlap syndrome, non-alcoholic fatty liver disease (non-alcoholic steatohepatitis), rheumatica, granuloma annulare, cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), lupus nephritis, drug-induced lupus, autoimmune myocarditis or myopericarditis, Dressler's syndrome, giant cell myocarditis, post-pericardiotomy syndrome, drug-induced hypersensitivity syndromes (including hypersensitivity myocarditis), eczema, sarcoidosis, erythema nodosum, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorders, MOG (myelin oligodendrocyte glycoprotein) antibody-associated disorders (including MOG-EM), optic neuritis, CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids), diffuse myelinoclastic sclerosis, Addison's disease, alopecia areata, ankylosing spondylitis, other spondyloarthritides (including peripheral spondyloarthritis, that is associated with psoriasis, inflammatory bowel disease, reactive arthritis or juvenile onset forms), antiphospholipid antibody syndrome, autoimmune hemolytic anaemia, autoimmune hepatitis, autoimmune inner ear disease, pemphigoid (including bullous pemphigoid, mucous membrane pemphigoid, cicatricial pemphigoid, herpes gestationis or pemphigoid gestationis, ocular cicatricial pemphigoid), linear IgA disease, Behçet's disease, celiac disease, Chagas disease, dermatomyositis, diabetes mellitus type I, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome and its subtypes (including acute inflammatory demyelinating polyneuropathy, AIDP, acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), pharyngeal-cervical-brachial variant,

Miller-Fisher variant and Bickerstaff's brainstem encephalitis), progressive inflammatory neuropathy, Hashimoto's disease, hidradenitis suppurativa, inclusion body myositis, necrotising myopathy, Kawasaki disease, IgA nephropathy, Henoch-Schonlein purpura, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura (TTP), Evans' syndrome, interstitial cystitis, mixed connective tissue disease, undifferentiated connective tissue disease, morphea, myasthenia gravis (including MuSK antibody positive and seronegative variants), narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, psoriatic arthritis, polymyositis, primary biliary cholangitis (also known as primary biliary cirrhosis), rheumatoid arthritis, palindromic rheumatism, schizophrenia, autoimmune (meningo-)encephalitis syndromes, scleroderma, Sjogren's syndrome, stiff person syndrome, polymylagia rheumatica, giant cell arteritis (temporal arteritis), Takayasu arteritis, polyarteritis nodosa, Kawasaki disease, granulomatosis with polyangitis (GPA; formerly known as Wegener's granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome), microscopic polyarteritis/polyangiitis, hypocomplementaemic urticarial vasculitis, hypersensitivity vasculitis, cryoglobulinemia, thromboangiitis obliterans (Buerger's disease), vasculitis, leukocytoclastic vasculitis, vitiligo, acute disseminated encephalomyelitis, adrenoleukodystrophy, Alexander's disease, Alper's disease, balo concentric sclerosis or Marburg disease, cryptogenic organising pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia), Canavan disease, central nervous system vasculitic syndrome, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic inflammatory demyelinating polyneuropathy (CIDP), diabetic retinopathy, globoid cell leukodystrophy (Krabbe disease), graft-versus-host disease (GVHD) (including acute and chronic forms, as well as intestinal GVHD), hepatitis C (HCV) infection or complication, herpes simplex viral infection or complication, human immunodeficiency virus (HIV) infection or complication, lichen planus, monomelic amyotrophy, fibrosis, cystic fibrosis, pulmonary arterial hypertension (PAH, including idiopathic PAH), lung sarcoidosis, idiopathic pulmonary fibrosis, kidney fibrosis, paediatric asthma, atopic dermatitis, allergic dermatitis, contact dermatitis, allergic rhinitis, rhinitis, sinusitis, conjunctivitis, allergic conjunctivitis, keratoconjunctivitis sicca, dry eye, xerophthalmia, glaucoma, macular oedema, diabetic macular oedema, central retinal vein occlusion (CRVO), macular degeneration (including dry and/or wet age related macular degeneration, AMD), post-operative cataract inflammation, uveitis (including posterior, anterior, intermediate and pan uveitis), iridocyclitis, scleritis, corneal graft and limbal cell transplant rejection, gluten sensitive enteropathy (coeliac disease), dermatitis herpetiformis, eosinophilic esophagitis, achalasia, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, aortitis and periaortitis, autoimmune retinopathy, autoimmune urticaria, Behcet's disease, (idiopathic) Castleman's disease, Cogan's syndrome, IgG4-related disease, retroperitoneal fibrosis, juvenile idiopathic arthritis including systemic juvenile idiopathic arthritis (Still's disease), adult-onset Still's disease, ligneous conjunctivitis,

Mooren's ulcer, pityriasis lichenoides et varioliformis acuta (PLEVA, also known as Mucha-Habermann disease), multifocal motor neuropathy (MMN), paediatric acute-onset neuropsychiatric syndrome (PANS) (including paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)), paraneoplastic syndromes (including paraneoplastic cerebellar degeneration, Lambert-Eaton myaesthenic syndrome, limbic encephalitis, brainstem encephalitis, opsoclonus myoclonus ataxia syndrome, anti-NMDA receptor encephalitis, thymoma-associated multiorgan autoimmunity), perivenous encephalomyelitis, reflex sympathetic dystrophy, relapsing polychondritis, sperm & testicular autoimmunity, Susac's syndrome, Tolosa-Hunt syndrome, Vogt-Koyanagi-Harada Disease, anti-synthetase syndrome, autoimmune enteropathy, immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX), microscopic colitis, autoimmune lymphoproliferative syndrome (ALPS), autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APEX), gout, pseudogout, amyloid (including AA or secondary amyloidosis), eosinophilic fasciitis (Shulman syndrome) progesterone hypersensitivity (including progesterone dermatitis), amilial Mediterranean fever (FMF), tumour necrosis factor (TNF) receptor-associated periodic fever syndrome (TRAPS), hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS), PAPA (pyogenic arthritis, pyoderma gangrenosum, severe cystic acne) syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), deficiency of the interleukin-36-receptor antagonist (DITRA), cryopyrin-associated periodic syndromes (CAPS) (including familial cold autoinflammatory syndrome [FCAS], Muckle-Wells syndrome, neonatal onset multisystem inflammatory disease [NOMID]), NLRP12-associated autoinflammatory disorders (NLRP12AD), periodic fever aphthous stomatitis (PFAPA), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), Majeed syndrome, Blau syndrome (also known as juvenile systemic granulomatosis), macrophage activation syndrome, chronic recurrent multifocal osteomyelitis (CRMO), familial cold autoinflammatory syndrome, mutant adenosine deaminase 2 and monogenic interferonopathies (including Aicardi-Goutières syndrome, retinal vasculopathy with cerebral leukodystrophy, spondyloenchondrodysplasia, STING [stimulator of interferon genes]-associated vasculopathy with onset in infancy, proteasome associated autoinflammatory syndromes, familial chilblain lupus, dyschromatosis symmetrica hereditaria), Schnitzler syndrome; familial cylindromatosis, congenital B cell lymphocytosis, OTULIN-related autoinflammatory syndrome, type 2 diabetes mellitus, insulin resistance and the metabolic syndrome (including obesity-associated inflammation), atherosclerotic disorders (e.g. myocardial infarction, angina, ischaemic heart failure, ischaemic nephropathy, ischaemic stroke, peripheral vascular disease, aortic aneurysm), renal inflammatory disorders (e.g. diabetic nephropathy, membranous nephropathy, minimal change disease, crescentic glomerulonephritis, acute kidney injury, renal transplantation).

24. The use according to claim 23, wherein the inflammatory disease or disease associated with an undesirable immune response is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, multiple sclerosis, psoriasis, inflammatory bowel disease (including ulcerative colitis and Crohn's disease), atopic dermatitis, fibrosis, uveitis, cryopyrin-associated periodic syndromes, Muckle-Wells syndrome, juvenile idiopathic arthritis, chronic obstructive pulmonary disease and asthma.

25. The use according to claim 22 wherein the cancer is selected from the group consisting of acute lymphoblastic leukaemia, adult; acute lymphoblastic leukaemia, childhood; acute myeloid leukaemia, adult; adrenocortical carcinoma; adrenocortical carcinoma, childhood; aids-related lymphoma; aids-related malignancies; anal cancer; astrocytoma, childhood cerebellar; astrocytoma, childhood cerebral; Barrett's esophagus (pre-malignant syndrome); bile duct cancer, extrahepatic; bladder cancer; bladder cancer, childhood; bone cancer, osteosarcoma/malignant fibrous histiocytoma; brain stem glioma, childhood; brain tumour, adult; brain tumour, brain stem glioma, childhood; brain tumour, cerebellar astrocytoma, childhood; brain tumour, cerebral astrocytoma/malignant glioma, childhood; brain tumour, ependymoma, childhood; brain tumour, medulloblastoma, childhood; brain tumour, supratentorial primitive neuroectodermal tumours, childhood; brain tumour, visual pathway and hypothalamic glioma, childhood; brain tumour, childhood (other); breast cancer; breast cancer and pregnancy; breast cancer, childhood; breast cancer, male; bronchial adenomas/carcinoids, childhood; carcinoid tumour, childhood; carcinoid tumour, gastrointestinal; carcinoma, adrenocortical; carcinoma, islet cell; carcinoma of unknown primary; central nervous system lymphoma, primary; cerebellar astrocytoma, childhood; cerebral astrocytoma/malignant glioma, childhood; cervical cancer; childhood cancers; chronic lymphocytic leukaemia; chronic myelogenous leukaemia; chronic myeloproliferative disorders; clear cell sarcoma of tendon sheaths; colon cancer; colorectal cancer; colorectal cancer, childhood; cutaneous t-cell lymphoma; endometrial cancer; ependymoma, childhood; epithelial cancer, ovarian; oesophageal cancer; oesophageal cancer, childhood; Ewing's family of tumours; extracranial germ cell tumour, childhood; extragonadal germ cell tumour; extrahepatic bile duct cancer; eye cancer, intraocular melanoma; eye cancer, retinoblastoma; gallbladder cancer; gastric (stomach) cancer; gastric (stomach) cancer, childhood; gastrointestinal carcinoid tumour; germ cell tumour, extracranial, childhood; germ cell tumour, extragonadal; germ cell tumour, ovarian; gestational trophoblastic tumour; glioma, childhood brain stem; glioma, childhood visual pathway and hypothalamic; hairy cell leukaemia; head and neck cancer; hepatocellular (liver) cancer; hepatocellular (liver) cancer, adult (primary); hepatocellular (liver) cancer, childhood (primary); cancer of the esophagus; Hodgkin's lymphoma; Hodgkin's lymphoma, adult; Hodgkin's lymphoma, childhood; Hodgkin's lymphoma during pregnancy; hypopharyngeal cancer; hypothalamic and visual pathway glioma, childhood; intraocular melanoma; islet cell carcinoma (endocrine pancreas); cancer of the endocrine system

(e.g., cancer of the thyroid, pancreas, parathyroid or adrenal glands); Kaposi's sarcoma; kidney cancer; laryngeal cancer; laryngeal cancer, childhood; leukaemia, acute lymphoblastic, adult; leukaemia, acute lymphoblastic, childhood; leukaemia, acute myeloid, adult; leukaemia, acute myeloid, childhood; leukaemia, chronic lymphocytic; leukaemia, chronic myelogenous; leukaemia, hairy cell; lymphocytic lymphoma; lip and oral cavity cancer; liver cancer, adult (primary); liver cancer, childhood (primary); lung cancer; lung cancer, non-small cell; lung cancer, small cell; lymphoblastic leukaemia, adult acute; lymphoblastic leukaemia, childhood acute; lymphocytic leukaemia, chronic; lymphoma, aids- related; lymphoma, central nervous system (primary); lymphoma, cutaneous t-cell; lymphoma, Hodgkin's, adult; lymphoma, Hodgkin's, childhood; lymphoma, Hodgkin's during pregnancy; lymphoma, non-Hodgkin's, adult; lymphoma, non-Hodgkin's, childhood; lymphoma, non-Hodgkin's during pregnancy; lymphoma, primary central nervous system; macroglobulinemia, Waldenstrom's; male breast cancer; malignant mesothelioma, adult; malignant mesothelioma, childhood; malignant thymoma; medulloblastoma, childhood; melanoma; melanoma, intraocular; Merkel cell carcinoma; mesothelioma, malignant; metastatic squamous neck cancer with occult primary; multiple endocrine neoplasia syndrome, childhood; multiple myeloma/plasma cell neoplasm; mycosis fungoides; myelodysplastic syndromes; myelogenous leukaemia, chronic; myeloid leukaemia, childhood acute; myeloma, multiple; myeloproliferative disorders, chronic; nasal cavity and paranasal sinus cancer; nasopharyngeal cancer; nasopharyngeal cancer, childhood; neoplastic cutaneous disease; neuroblastoma; non-Hodgkin's lymphoma, adult; non-Hodgkin's lymphoma, childhood; non-Hodgkin's lymphoma during pregnancy; non-small cell lung cancer; neoplasms of the central nervous system (e.g., primary CNS lymphoma, spinal axis tumors, medulloblastoma, brain stem gliomas or pituitary adenomas); oat-cell cancer; oral cancer, childhood; oral cavity and lip cancer; oropharyngeal cancer; osteosarcoma/malignant fibrous histiocytoma of bone; ovarian cancer; ovarian cancer, childhood; ovarian epithelial cancer; ovarian germ cell tumour; ovarian low malignant potential tumour; pediatric malignancy; pancreatic cancer; pancreatic cancer, childhood; pancreatic cancer, islet cell; paranasal sinus and nasal cavity cancer; parathyroid cancer; penile cancer; pheochromocytoma; pineal and supratentorial primitive neuroectodermal tumours, childhood; pituitary tumour; plasma cell neoplasm/multiple myeloma; pleuropulmonary blastoma; pregnancy and breast cancer; pregnancy and Hodgkin's lymphoma; pregnancy and non-Hodgkin's lymphoma; primary central nervous system lymphoma; primary liver cancer, adult; primary liver cancer, childhood; prostate cancer (particularly hormone-refractory); chronic or acute leukemia; solid tumors of childhood; hypereosinophilia; rectal cancer; renal cell (kidney) cancer; renal cell cancer, childhood; renal pelvis and ureter, transitional cell cancer; retinoblastoma; rhabdomyosarcoma, childhood; salivary gland cancer; salivary gland cancer, childhood; sarcoma, Ewing's family of tumours; sarcoma, Kaposi's; sarcoma (osteosarcoma)/malignant fibrous histiocytoma of bone; sarcoma, rhabdomyosarcoma, childhood; sarcomas of soft tissues; sarcoma, soft tissue, adult; sarcoma, soft tissue, childhood;

Sezary syndrome; skin cancer; skin cancer, childhood; skin cancer (melanoma); skin carcinoma, Merkel cell; small cell lung cancer; dermatofibrosarcoma protuberans; small intestine cancer; soft tissue sarcoma, adult; soft tissue sarcoma, childhood; cancer of the head and neck; squamous neck cancer with occult primary, metastatic; stomach (gastric) cancer; stomach (gastric) cancer, childhood; supratentorial primitive neuroectodermal tumours, childhood; t-cell lymphoma, cutaneous; testicular cancer; thymoma, childhood; thymoma, malignant; thyroid cancer; thyroid cancer, childhood; transitional cell cancer of the renal pelvis and ureter; trophoblastic tumour, gestational; unknown primary site, cancer of, childhood; unusual cancers of childhood; ureter and renal pelvis, transitional cell cancer; urethral cancer; cancer of the ureter (e.g., renal cell carcinoma, carcinoma of the renal pelvis); cancer of the penis; gynecologic tumors; uterine cancer; uterine sarcoma; carcinoma of the fallopian tubes; carcinoma of the endometrium; vaginal cancer; carcinoma of the vagina; carcinoma of the vulva; visual pathway and hypothalamic glioma, childhood; vulvar cancer; Waldenstrom's macro globulinemia; and Wilms' tumour.

26. The use according to any one of claims 21 to 25, wherein the medicament is to be administered in combination with a further therapeutic agent selected from the group consisting of:

- a corticosteroid (glucocorticoid), retinoid (e.g. acitretin, isotretinoin, tazarotene), anthralin, vitamin D analogue (e.g. cacitriol, calcipotriol), calcineurin inhibitors (e.g. tacrolimus, pimecrolimus), phototherapy or photochemotherapy (e.g. psoralen ultraviolet irradiation, PUVA) or other form of ultraviolet light irradiation therapy, ciclosporine, a thiopurine (e.g. azathioprine, 6-mercaptopurine), methotrexate, an anti-TNFα agent (e.g. infliximab, etanercept, adalimumab, certolizumab, golimumab or a biosimilar), phosphodiesterase-4 (PDE4) inhibitors (e.g. apremilast, crisaborole), anti-IL-17 agent (e.g. brodalumab, ixekizumab, secukinumab), anti-IL12/IL-23 agent (e.g. ustekinumab, briakinumab), anti-IL-23 agent (e.g. guselkumab, tildrakizumab), JAK (Janus Kinase) inhibitor (e.g. tofacitinib, ruxolitinib, baricitinib, filgotinib, upadacitinib), plasma exchange, intravenous immune globulin (IVIG), cyclophosphamide, anti-CD20 B cell depleting agent (e.g. rituximab, ocrelizumab, ofatumumab, obinutuzumab), anthracycline analogue (e.g. mitoxantrone), cladribine, sphingosine 1-phosphate receptor modulator or sphingosine analogue (e.g. fingolimod, siponimod, ozanimod, etrasimod), interferon beta preparation (including interferon beta 1b/1a), glatiramer, anti-CD3 therapy (e.g. OKT3), anti-CD52 targeting agent (e.g. alemtuzumab), leflunomide, teriflunomide, gold compound, laquinimod, potassium channel blocker (e.g. dalfampridine/4-aminopyridine), mycophenolic acid, mycophenolate mofetil, purine analogue (e.g. pentostatin), mTOR (mechanistic target of rapamycin) pathway inhibitor (e.g. sirolimus, everolimus), anti-thymocyte globulin (ATG), IL-2 receptor (CD25) inhibitor (e.g. basiliximab, daclizumab), anti-IL-6 receptor or anti-IL-6 agent (e.g. tocilizumab, siltuximab), Bruton's tyrosine kinase (BTK) inhibitor (e.g. ibrutinib), tyrosine kinase inhibitor (e.g. imatinib), ursodeoxycholic acid, hydroxychloroquine, chloroquine, B cell activating factor (BAFF, also

known as BlyS, B lymphocyte stimulator) inhibitor (e.g. belimumab, blisibimod), other B cell targeted therapy including a fusion protein targeting both APRIL (A Proliferation-Inducing Ligand) and BlyS (e.g. atacicept), PI3K inhibitor including pan-inhibitor or one targeting the p110δ and/or p110γ containing isoforms (e.g. idelalisib, copanlisib, duvelisib), an interferon α receptor inhibitor (e.g. anifrolumab, sifalimumab), T cell co-stimulation blocker (e.g. abatacept, belatacept), thalidomide and its derivatives (e.g. lenalidomide), dapsone, clofazimine, a leukotriene antagonist (e.g. montelukast), theophylline, anti-IgE therapy (e.g. omalizumab), an anti-IL-5 agent (e.g. mepolizumab, reslizumab), a long-acting muscarinic agent (e.g. tiotropium, aclidinium, umeclidinium), a PDE4 inhibitor (e.g. roflumilast), riluzole, a free radical scavenger (e.g. edaravone), a proteasome inhibitor (e.g. bortezomib), a complement cascade inhibitor including one directed against C5 (e.g. eculizumab), immunoadsor, antithymocyte globulin, 5-aminosalicylates and their derivatives (e.g. sulfasalazine, balsalazide, mesalamine), an anti-integrin agent including one targeting α4β1 and/or α4β7 integrins (e.g. natalizumab, vedolizumab), an anti-CD11-α agent (e.g. efalizumab), a non-steroidal anti-inflammatory drug (NSAID) including a salicylate (e.g. aspirin), a propionic acid (e.g. ibuprofen, naproxen), an acetic acid (e.g. indomethacin, diclofenac, etodolac), an oxicam (e.g. meloxicam) a fenamate (e.g. mefenamic acid), a selective or relatively selective COX-2 inhibitor (e.g. celecoxib, etroxicoxib, valdecoxib and etodolac, meloxicam, nabumetone), colchicine, an IL-4 receptor inhibitor (e.g. dupilumab), topical/contact immunotherapy (e.g. diphenylcyclopropenone, squaric acid dibutyl ester), anti-IL-1 receptor therapy (e.g. anakinra), IL-1β inhibitor (e.g. canakinumab), IL-1 neutralising therapy (e.g. rilonacept), chlorambucil, a specific antibiotic with immunomodulatory properties and/or ability to modulate NRF2 (e.g. tetracyclines including minocycline, clindamycin, macrolide antibiotics), anti-androgenic therapy (e.g. cyproterone, spironolactone, finasteride), pentoxifylline, ursodeoxycholic acid, obeticholic acid, fibrate, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, a VEGF (vascular endothelial growth factor) inhibitor (e.g. bevacizumab, ranibizumab, pegaptanib, aflibercept), pirfenidone or mizoribine;


- a palliative treatment such as selected from the group consisting of: antiemetic agents, medication intended to alleviate pain such as opioids, medication used to decrease high blood uric acid levels such as allopurinol or rasburicase, anti-depressants, sedatives, anti-convulsant drugs, laxatives, anti-diarrhoeal drugs and/or antacids;

- an additional cancer treatment selected from the group consisting of chemotherapy, a targeted therapy, immunotherapy and an hormonal therapy;

- a gastric or pancreatic lipase inhibitor (such as orlistat); a lipid lowering agent (such as a statin, a fibrate, niacin or a derivative thereof (such as acipimox), lecithin, a bile acid sequesterant, ezetimibe, lomitapide, a phytosterol, an omega-3 supplement, a PCSK9 inhibitor); a CB-1 antagonist; a lipoxygenase inhibitor; a somostatin analogue; an insulin compound or insulin analogue (such as human insulin, insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec); an insulin sensitising agent such as a PPAR-gamma agonist, PPAR-

alpha agonist or mixed PPAR-gamma/alpha agonist (such as metformin, pioglitazone or rosiglitazone); an insulin secretagogue (such as a nateglinide or repaglinide, or a sulfonylurea such as gliclazide, glimeperide, limepiride, glyburide); an SGLT2 inhibitor (such as dapagliflozin, canagliflozin or empagliflozin); an amylin analogue (such as pramlintide); a DPPIV inhibitor (such as sitagliptin, saxagliptin, linagliptin, alogliptin or vildagliptin); a GLP-1 agonist (such as albiglutide, dulaglutide, exenatide, liraglutide, semaglutide or lixisenatide); an alpha-glucosidase inhibitor (such as acarbose, miglitol or voglibose); a phosphodiesterase inhibitor (such as pentoxifylline); a glycogen phosphorylase inhibitor; an MCH-1 antagonist; a glucokinase activator; a glucagon antagonist; an insulin signalling agonist; a PTP1B inhibitor; a gluconeogenesis inhibitor; and a GSK inhibitor or a galanin receptor agonist.


27. A process for preparing a compound of formula (Ia) as described in any one of claims 1 to 18, or a salt, such as a pharmaceutically acceptable salt and/or solvate thereof, which comprises reacting a compound of formula (IIa-S):



(IIa-S) ;

or a salt thereof;

with a compound of formula (IIIa-S):




(IIIa-S) ;

wherein R^A, R^B, R^C, R^D, Y^1, Y^2, Y^3, X and m are defined according to any one of claims 1 to 17, and LG^2 is a leaving group such as halo (e.g. chloro, bromo or iodo), OMs or OTs.

28. A compound selected from the group consisting of:

- compound of formula (IIa-S):




(IIa-S) ;

or a salt and/or solvate thereof;

wherein R^A, Y^1, Y^2, Y^3 and X are defined according to any one of claims 1 to 8, 14, 16 or 17;

- compound of formula (IVa):




(IVa)

or a salt and/or solvate thereof;

wherein Y^1, Y^2 and Y^3 are defined in any one of claims 1 to 18, and LG is a leaving group such as halo, OMs or OTs;

- compound of formula (Va):




(Va)

or a salt and/or solvate thereof;

wherein R^A, Y^1, Y^2 and Y^3 are defined in any one of claims 1 to 18;

- compound of formula (VIa):




(VIa)

or a salt and/or solvate thereof;

wherein R^B, R^C, R^D, m, Y^1, Y^2 and Y^3 are defined in any one of claims 1 to 18 and LG^1 is a leaving group such as halo (e.g. chloro, bromo or iodo), OMs or OTs;

- compound of formula (VIIa):



(VIIa)

or a salt and/or solvate thereof;

wherein R^A, R^B, R^C, R^D, m, Y^1, Y^2 and Y^3 are defined in any one of claims 1 to 17.

29. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 18 which is a pharmaceutically acceptable salt of the compound of formula (Ia).

30. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 18 which is the compound of formula (Ia).